This paper is marked retracted in the scholarly record (OpenAlex). Interpret its findings with caution.
Retraction: Astragaloside IV (AS-IV) alleviates the malignant biological behavior of hepatocellular carcinoma via Wnt/β-catenin signaling pathway
ZhongYu Jiang, Zhen Mao
TL;DR
This paper is a retraction of a previous study that claimed Astragaloside IV reduces liver cancer aggression through a specific signaling pathway.
Contribution
The retraction highlights the correction or removal of previously published findings on Astragaloside IV's effect on hepatocellular carcinoma.
Findings
The original study's claims about Astragaloside IV's impact on liver cancer were retracted.
The retraction suggests potential issues with the validity of the original research findings.
Abstract
Retraction of ‘Astragaloside IV (AS-IV) alleviates the malignant biological behavior of hepatocellular carcinoma via Wnt/β-catenin signaling pathway’ by ZhongYu Jiang et al., RSC Adv., 2019, 9, 35473–35482, https://doi.org/10.1039/C9RA05933D.
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsCancer Mechanisms and Therapy · Traditional Chinese Medicine Analysis · Neurological Disease Mechanisms and Treatments